Bayer/Schering-Plough/Shionogi's Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
Posted on: Thursday, 17 April 2008, 09:01 CDT
WALTHAM, Mass., April 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy's overall clinical efficacy (defined as cure or improvement of symptoms) is the attribute that most influences primary care physicians' prescribing decisions for community-acquired pneumonia. Clinical data and expert opinion show that Bayer/Schering-Plough/Shionogi's Avelox (moxifloxacin) is similar in overall clinical efficacy to the market leader levofloxacin -- Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit. However, Avelox's advantages in bacteriological efficacy, spectrum of activity, and activity against key antibiotic-resistant pathogens earn the agent gold standard status for community acquired pneumonia.
The new report entitled Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists finds that, through 2016, there are no therapies in development that will displace Avelox as the clinical gold standard for the treatment of community-acquired pneumonia. Although levofloxacin is superior to Avelox in the areas of safety and delivery -- offering a lower incidence of dermatological reactions and a five-day course of treatment -- Avelox outperforms levofloxacin on efficacy measures such as bacteriological eradication and activity against penicillin-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus.
"Based on available data and expert opinion, we do not expect any therapy under development for community-acquired pneumonia to displace Avelox as the clinical gold standard for this indication through 2016," said John Lebbos, M.D. director at Decision Resources. "While some therapies in development for community-acquired pneumonia hold promise, most of them have efficacy, safety and/or delivery features that are inferior when compared with Avelox."
About the Report
Community-Acquired Pneumonia: In a Crowded Generics-Dominated Market, Room for New Agents Still Exists is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (http://www.decisionresources.com/ ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Delta Dental Awards $50,000 Grant to Georgia Tech to Improve Quality and Access to Care in Community Clinics
- Medical Ventures to Acquire Two Vascular Device Developers
- Acciona Acquires 1300 MW of Development Assets in Midwest
- Southern California Clinics Seek to Improve Quality of Care Through Technological Advances; Study Underway at 50 Southern California Community Clinics To Improve Access and Care for the Uninsured
- Siemens Strengthens SOA Leadership Role By Exposing Key HiPath Enterprise Communication Functions to Developers for Business Process Integrations
- Internal Relationship Management: Linking Human Resources to Market Performance
- SD Pharmaceuticals Completes Pivotal Pre-Clinical Efficacy Study on Its Novel and Less Toxic Docetaxel Formulation
- Great River Energy Issues Request for Renewable Energy Proposals, Including Community-Based Energy Development (C-BED)
- CORDIS Unit, the Office of the European Community, Research and Development Information Service, Grants License to XRAYMEDIA
- New Study Demonstrates Clinical Efficacy of Telithromycin Superior to Standard First-Line Antibiotic Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia (CAP)
 |
 |
User Comments (0)
RSS Feeds